Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Linch

Showing results (291-300 of 304) with videos related to

Pageof 31
Sort By:
British Journal of Cancer|October 3, 1999
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AMLC N Harrison, W Gregory, G V Hudson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatmentA J Swerdlow, M J Schoemaker, R Allerton, et al.
Blood|August 1, 1996
Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation StudyM E Hill, K A MacLennan, D C Cunningham, et al.
Leukemia & Lymphoma|May 11, 2002
Survival and freedom from progression in autotransplant lymphoma patients is independent of stem cell source: further follow-up from the original randomised study to assess engraftmentP D Kottaridis, K Peggs, N Schmitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphomaT J Smith, B E Hillner, N Schmitz, et al.
British Journal of Haematology|January 31, 1998
G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trialD C Linch, D W Milligan, D A Winfield, et al.
Blood|September 6, 2001
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trialsP D Kottaridis, R E Gale, M E Frew, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trialA K McMillan, E H Phillips, A A Kirkwood, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2000
A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphomaD C Linch, P Smith, B W Hancock, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 5, 2006
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL)D C Betticher, G Martinelli, J A Radford, et al.
Pageof 31

Showing results (291-300 of 304) with videos related to

Sort By:
Pageof 31
British Journal of Cancer|October 3, 1999
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AMLC N Harrison, W Gregory, G V Hudson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatmentA J Swerdlow, M J Schoemaker, R Allerton, et al.
Blood|August 1, 1996
Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation StudyM E Hill, K A MacLennan, D C Cunningham, et al.
Leukemia & Lymphoma|May 11, 2002
Survival and freedom from progression in autotransplant lymphoma patients is independent of stem cell source: further follow-up from the original randomised study to assess engraftmentP D Kottaridis, K Peggs, N Schmitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphomaT J Smith, B E Hillner, N Schmitz, et al.
British Journal of Haematology|January 31, 1998
G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trialD C Linch, D W Milligan, D A Winfield, et al.
Blood|September 6, 2001
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trialsP D Kottaridis, R E Gale, M E Frew, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trialA K McMillan, E H Phillips, A A Kirkwood, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2000
A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphomaD C Linch, P Smith, B W Hancock, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 5, 2006
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL)D C Betticher, G Martinelli, J A Radford, et al.
Pageof 31